Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,039 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (two doses) Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Micronized progesterone, Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Oxytocin and Approach-avoid in Grief

NCT04505904
View directory record Official record
Conditions
Prolonged Grief Disorder, Bereavement
Interventions
Syntocinon, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 14, 2026, 2:52 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 14, 2026, 2:52 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

NCT02837952
View directory record Official record
Conditions
Pain
Interventions
FDC IBU/APAP 250 mg/500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 14, 2026, 2:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Lipoic Acid as a Treatment for Acute Optic Neuritis

NCT01294176
View directory record Official record
Conditions
Optic Neuritis
Interventions
Lipoic Acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ACE527 Safety and Immunogenicity Study

NCT00901654
View directory record Official record
Conditions
Enterotoxigenic E. Coli (ETEC) Infection
Interventions
ACE527 vaccine, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 14, 2026, 2:52 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

NCT04644003
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
STP1, Placebo
Drug
Lead sponsor
Stalicla SA
Industry
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 14, 2026, 2:52 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.

NCT01377441
View directory record Official record
Conditions
Inflammatory Response
Interventions
Ibuprofen, Placebo/Saline solution
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
81
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 14, 2026, 2:52 AM EDT
Terminated Phase 2 Interventional Results available

VB-111 in Surgically Accessible Recurrent/Progressive GBM

NCT04406272
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
VB11, Surgery, Placebo, Bevacizumab
Drug · Procedure · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

NCT04825288
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
30
States / cities
Tucson, Arizona • Burbank, California • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Results available

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Buena Park, California • Chino, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

NCT02834741
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NYX-2925
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

NCT03207945
View directory record Official record
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections
Interventions
Alirocumab, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 14, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

NCT00615966
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Diannexin, Placebo
Drug
Lead sponsor
Alavita Pharmaceuticals Inc
Industry
Eligibility
21 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • Livingston, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 14, 2026, 2:52 AM EDT